Real-world long-term continuation of lecanemab therapy and the clinical utility of phosphorylated tau 181.

Noguchi-Shinohara M, Muramatsu D, Shima A, Sakashita Y, Tada Y, Yamaguchi H, Komatsu J, Ikeda T, Ono K

Open source

DOI
10.1016/j.tjpad.2026.100664
Published
2026 Aug 28
Container
The journal of prevention of Alzheimer's disease
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.tjpad.2026.100664,
  title = {Real-world long-term continuation of lecanemab therapy and the clinical utility of phosphorylated tau 181.},
  author = {Noguchi-Shinohara M and Muramatsu D and Shima A and Sakashita Y and Tada Y and Yamaguchi H and Komatsu J and Ikeda T and Ono K},
  year = {2026},
  journal = {The journal of prevention of Alzheimer's disease},
  doi = {10.1016/j.tjpad.2026.100664},
  url = {https://doi.org/10.1016/j.tjpad.2026.100664}
}

RIS

TY  - JOUR
TI  - Real-world long-term continuation of lecanemab therapy and the clinical utility of phosphorylated tau 181.
AU  - Noguchi-Shinohara M
AU  - Muramatsu D
AU  - Shima A
AU  - Sakashita Y
AU  - Tada Y
AU  - Yamaguchi H
AU  - Komatsu J
AU  - Ikeda T
AU  - Ono K
PY  - 2026
JO  - The journal of prevention of Alzheimer's disease
DO  - 10.1016/j.tjpad.2026.100664
UR  - https://doi.org/10.1016/j.tjpad.2026.100664
ER  - 

APA

M, N., D, M., A, S., Y, S., Y, T., H, Y., J, K., T, I., & K, O. (2026). Real-world long-term continuation of lecanemab therapy and the clinical utility of phosphorylated tau 181.. The journal of prevention of Alzheimer's disease. https://doi.org/10.1016/j.tjpad.2026.100664

Source records